ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Perennial Allergic Rhinitis
Conditions
Perennial Allergic Rhinitis
Trial Timeline
Feb 1, 2011 โ Apr 1, 2011
NCT ID
NCT01287364About ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation is a phase 3 stage product being developed by Sumitomo Pharma for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01287364. Target conditions include Perennial Allergic Rhinitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01287364 | Phase 3 | Completed |
Competing Products
20 competing products in Perennial Allergic Rhinitis